About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Rheumatology Research Group (GRR) is focused on translational research in immunity-mediated inflammatory diseases (IMIDA), mainly in the area of rheumatology. The GRR is a multidisciplinary group made up of clinical specialists, biologists, bioinformaticians and laboratory technicians. The different research lines of the GRR emphasize the use of high-performance technologies for the study at the cellular and molecular level of the immununopathology of IMIDA, mainly chronic inflammatory arthritis and autoimmune systemic diseases.
At the clinical level, we have developed lines of research in very diverse areas of rheumatology, including chronic inflammatory arthritis (rheumatoid arthritis, spondyloarthropathies), systemic autoimmune diseases (lupus, myositis, Sjögren's syndrome), the study of musculoskeletal imaging, pediatric rheumatology (juvenile idiopathic arthritis, autoimmune systemic diseases, autoinflammatory syndromes), central sensitization syndromes and the study of bone metabolism. One of the main objectives of the GRR is the coordination of basic and clinical research to accelerate the transfer of knowledge to clinical practice and thus improve the quality of life of patients.
IP: José Alegre Martin Collaborators: Jesus Castro Marrero, Jesus Castro Marrero, Jesus Castro Marrero, Jesus Castro Marrero, Jesus Castro Marrero, Jesus Castro Marrero, Jesus Castro Marrero, Jesus Castro Marrero Funding agency: Instituto de Salud Carlos III Funding: 87120 Reference: PI19/00629 Duration: 01/01/2020 - 30/06/2024
IP: Josefina Cortes Hernandez Collaborators: Teresa Moline Marimon, Sheila Bermejo Garcia Funding agency: Instituto de Salud Carlos III Funding: 141570 Reference: PI21/00287 Duration: 01/01/2022 - 31/12/2024
IP: Antonio Julia Cano Collaborators: Juan Jose De Agustin De Oro, Nuria Palau Balaña, Estratificación de pacientes con artritis reumatoide en la terapia anti-TNF. Caracterización espacial del transcriptoma de la me Funding agency: Instituto de Salud Carlos III Funding: 196020 Reference: PI21/01185 Duration: 01/01/2022 - 30/06/2026
IP: Cristina Solé Marce Collaborators: Berta Ferrer Fábrega, Gloria Aparicio Español Funding agency: Instituto de Salud Carlos III Funding: 99099 Reference: PI21/01869 Duration: 01/01/2022 - 31/12/2025
The new therapeutic strategy aims at maintaining the efficacy of thalidomide while avoiding its main systemic adverse effects.
The event, held as part of World Lupus Day, incorporated the perspective of people living with the disease to address the challenges associated with lupus.
The global biopharmaceutical company UCB has acquired the data and clinical knowledge business of IMIDomics, a spin-off of the Vall d’Hebron Institute of Research (VHIR).
